3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Conditions
Ovarian Neoplasms
2
Fallopian Tube Neoplasms
2
Endometrial Neoplasms
2
Recurrence
1
Neoplasms
1
Neoplasm Metastasis
1
Interventions
pembrolizumab
43
Nivolumab
24
Gemcitabine
23
Cyclophosphamide
22
Paclitaxel
17
Capecitabine
16
fludarabine
15
Ipilimumab
14
aldesleukin
11
Docetaxel
11
130-nm albumin-bound paclitaxel
11
Trastuzumab
10
Cetuximab
10
Bevacizumab
10
Albumin-Bound Paclitaxel
9
fludarabine phosphate
8
Specimen Handling
8
Interleukin-2
8
Fluorouracil
8
Cisplatin
8
Biopsy
8
Radiosurgery
7
Oxaliplatin
7
Irinotecan
7
durvalumab
6
avelumab
6
Temozolomide
6
Pemetrexed
6
Leucovorin
6
Carboplatin
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Neoplasm Metastasis
×
sarilumab
×
Clear all
NCT04333706
2026-03-10
EMPOWER
University of Southern California
Phase 1/2
Recruiting
65 enrolled